Meeting
2014 Gastrointestinal Cancers Symposium
Relationship of ethnicity and overall survival (OS) in Asian patients (pts) on sorafenib for advanced hepatocellular carcinoma (HCC) in British Columbia, Canada.
Authors
Renata D'Alpino Peixoto
BC Cancer Agency, Vancouver, BC, Canada
Renata D'Alpino Peixoto , Daniel John Renouf , Sharlene Gill , Winson Y. Cheung , Hagen F. Kennecke , Howard John Lim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 311)
DOI
10.1200/jco.2014.32.3_suppl.311
Abstract #
311
Poster Bd #
C26
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Relationship between ethnicity and overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S).
First Author: Daniel E. Meyers
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Evaluating the safety and efficacy of the addition of liver radiation (RT) to atezolizumab and bevacizumab (A/B) in advanced hepatocellular carcinoma (HCC): A retrospective cohort analysis.
First Author: Timothy J. Brown
Poster
2018 Gastrointestinal Cancers Symposium
Nivolumab in advanced hepatocellular carcinoma (HCC) and Child Pugh B (CPB) cirrhosis: Safety and clinical outcomes in a retrospective case series.
First Author: Swetha Kambhampati
Poster
2017 Gastrointestinal Cancers Symposium
Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study.
First Author: Ignacio Melero